|
|
 |
|
EXEL: Exelixis Inc - Stock News |
Enter Ticker:
|
|
| Nov 19, 2009 |
BiomedReports: News and FDA Updates for Depomed (NASDAQ:DEPO), Exelixis (Nasdaq:EXEL), PPD (NASDAQ:PPDI) |
| Nov 18, 2009 |
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference |
| Nov 18, 2009 |
Exelixis (EXEL) Downgrade Alert, Watch for 7.9% Technical Uptrend Reversal |
| Nov 18, 2009 |
BiomedReports: News and FDA Updates for DARA (NASDAQ:DARA), Exelixis (Nasdaq:EXEL), ImmunoGen (Nasdaq:IMGN) |
| Nov 18, 2009 |
Analyst Downgrades for November 18th |
| Nov 17, 2009 |
Exelixis Up 5.8% Since SmarTrend's Buy Recommendation |
| Nov 17, 2009 |
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference |
| Nov 16, 2009 |
BiomedReports: News and FDA Updates for China-Biotics (Nasdaq:CHBT), NovaBay (NYSE:NBY), Exelixis (Nasdaq:EXEL) |
| Nov 13, 2009 |
Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference |
| Nov 11, 2009 |
Complimentary Sector & Company Analysis on ABAT, EXEL, LBTYA, BEBE,INTU and BIIB From TheFortuneFinancial.com |
| Nov 03, 2009 |
BiomedReports: News and FDA Updates for AMRI (NASDAQ:AMRI), GTC (NASDAQ:GTCB), Ligand (NASDAQ:LGND), Exelixis (NASDAQ:EXEL) |
| Nov 02, 2009 |
Ligand Updates License Agreement with Exelixis |
| Oct 29, 2009 |
Exelixis Reaffirms |
| Oct 20, 2009 |
Exelixis to Webcast 3Q 2009 Conference Call |
| Oct 19, 2009 |
Exelixis Up 13.6% Since SmarTrend's Buy Recommendation |
| |
| ZACKS COMMENTARY FOR EXEL |
|
|
|
Sponsored Links 
0.08